• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Labcorp launches at-home collection device for diabetes risk testing

May 17, 2022 By Sean Whooley

Labcorp Weavr Velvet
[Image from Labcorp]
Labcorp (NYSE:LH) announced today that it launched an at-home collection kit that measures HbA1c from a small blood sample.

Burlington, North Carolina-based Labcorp’s first-of-its-kind diagnostic offering uses a collection device from Weavr Health and is offered through its Labcorp OnDemand platform.

The company said in a news release that it’s the only commercial laboratory to provide HbA1c (hemoglobin A1c) testing and the only one to receive approval from the New York State Clinical Laboratory Evaluation Program for testing using the Weavr Velvet blood collection device, allowing for the diabetes risk test to be made available nationwide.

Labcorp designed its OnDemand diabetes risk test to use a dried blood technology to offer a snapshot of the body’s average blood sugar levels over time through a fingerprick. Weavr Velvet separates plasma and red blood cells for the analysis of the sample, keeping it contained, safe and stable for transport and testing. Following collection, the device is returned to Labcorp through a prepaid FedEx envelope.

“Diabetes is a serious disease affecting millions of people in the United States,” Labcorp Diagnostics CMO and President Dr. Brian Caveney said in the release. “Our Labcorp OnDemand diabetes risk test at-home collection kit now makes it easier for consumers to understand their diabetes risk and health status using an innovative and approved collection device. This test offers a convenient way for more people to manage their health and stay informed, so they can seek treatment that may lead to better health outcomes.”

The company said samples collected with the Weavr Velvet device demonstrated better than 97% accuracy when compared to traditional blood draws. The device was co-developed for HbA1c testing by the two companies through an equity investment made by Labcorp, as Weavr remains the device owner.

“Through our collaboration with Labcorp, we are able to bring safe, efficient testing to doorsteps across the country,” Weavr Health CEO Linh Hoang said. “Our goal is to create innovative testing solutions so that people in all communities have access to life-saving diagnostics and feel empowered to take control of their health.”

Filed Under: Diabetes, Diagnostics, Featured Tagged With: LabCorp, Weavr Health

IN CASE YOU MISSED IT

  • Enable Injections, Sanofi obtain approval for on-body myeloma therapy in Japan
  • Abbott sets Libre Duo glucose-ketone sensor US launch for December
  • Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes
  • MiniMed completes split from Medtronic
  • Insulet’s Omnipod Discover data platform begins full US rollout

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS